- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04744090
Roflumilast as add-on Therapy in Early Cases of ARDS
The Potential Anti-inflammatory Effect of Roflumilast as Add-on Therapy in The Management of Hospitalized Patients With Mild Acute Respiratory Distress Syndrome
- Mild cases of ARDS will be included in a two-arm protocol, to receive 500 mcg of roflumilast daily up to 28 days (FDA approved dose for COPD) plus standard of care versus standard of care alone.
- Approximately 76 hospitalized patients with ARDS will be enrolled in this study.
- Eligible patients will be randomized at ratio of (1:1) to receive either roflumilast plus standard of care or standard of care alone.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
• Methodology in details:
- Informed consent will be obtained from included participants.
- Mild cases of ARDS will be included in a two-arm protocol, to receive 500 mcg of roflumilast daily up to 28 days (FDA approved dose for COPD) plus standard of care versus standard of care alone.
- Approximately 76 hospitalized patients with ARDS will be enrolled in this study.
- Eligible patients will be randomized at ratio of (1:1) to receive either roflumilast plus standard of care or standard of care alone.
- Randomization:
Randomization will be in 1:1 ratio using permuted blocks of different sizes. Random.org website will be used for random selection of a sequence of blocks. The latter will be used to generate a randomized list which will be generated and stored by a third party independent of the study team. For allocation concealment, the list will be used to make sequentially numbered sealed opaque envelopes, each containing the sequential randomization number and allocation of subsequent cases. Envelopes will be handed to the study team member responsible for medication preparation. Each envelope will be opened only after:
- Screening for eligibility
- Obtaining consent
Recording baseline characters The treatment allocation dictated in the envelope will be documented in the case record form and will be subject to audit to assure correct randomization according to the original list.
- Intervention:
Drug: Roflumilast
- Roflumilast 500 mcg daily for up to 28 days
- Total follow up time will be 28 days.
- Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.
- Roflumilast will be combined with standard of care for ARDS.
- During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.
- During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.
- In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Cairo University Hospitals
-
-
Doki
-
Giza, Doki, Egypt
- Misr International Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to sign informed consent
- Patients >18 years old male or female
- Mild cases of ARDS according to the Berlin criteria (PaO/FiO 200 to 300 mmHg)
Exclusion Criteria:
- Pregnancy and breast feeding
- History of hypersensitivity to roflumilast
- Patients with mechanical respiratory assistance (severe ARDS)
- Patients under treatment with roflumilast for COPD
- Patients with psychiatric diseases
- Hepatic cirrhosis (Child-Pugh score B or C)
- Refused to sign informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Roflumilast add-on
Eligible patients will take 500 Mcg of roflumilast once daily (up to 28 days) plus standard of care.
|
|
PLACEBO_COMPARATOR: Placebo control
Eligible patients will take placebo plus standard of care.
|
Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in clinical picture (two-point reduction in patient's admission status)
Time Frame: Follow up for up to 28 days.
|
Defined as a two-point reduction in patient's admission status on a five-point ordinal scale, or live discharge from hospital whichever came first. • The five-point ordinal scale is as follow:
|
Follow up for up to 28 days.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of change in systemic inflammatory parameters, including ferritin.
Time Frame: Weekly assessment (baseline, day7, day14, at the end) for up to 28 days.
|
Weekly assessment (baseline, day7, day14, at the end) for up to 28 days.
|
Evaluation of change in systemic inflammatory parameters, including CRP.
Time Frame: Weekly assessment (baseline, day7, day14, at the end) for up to 28 days.
|
Weekly assessment (baseline, day7, day14, at the end) for up to 28 days.
|
Evaluation of change in systemic inflammatory parameters, including LDH.
Time Frame: Weekly assessment (baseline, day7, day14, at the end) for up to 28 days.
|
Weekly assessment (baseline, day7, day14, at the end) for up to 28 days.
|
Total hospital stay.
Time Frame: Follow up for up to 28 days.
|
Follow up for up to 28 days.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eman A Abdel Rasheed, Professor, Cairo University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MS-292-2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Distress Syndrome, Adult
-
Centre Hospitalier Universitaire de NiceCompletedRespiratory Distress Syndrome,AdultFrance
-
Abbott NutritionTerminatedAcute Lung Injury | Respiratory Distress Syndrome,AdultRussian Federation
-
Wolfson Medical CenterUnknown
-
GlaxoSmithKlineTerminatedLung Injury, Acute and Respiratory Distress Syndrome, AdultUnited Kingdom
-
Amazon UniversitySanta Casa de Misericórdia do ParáCompletedSepsis | HELLP Syndrome | Postpartum Period | Respiratory Distress Syndrome,Adult
-
Dompé Farmaceutici S.p.ARecruitingAcute Respiratory Distress Syndrome, AdultUnited States, Germany, Italy
-
University Hospital TuebingenCompletedRespiratory Distress Syndrome, AdultGermany
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedRespiratory Distress Syndrome, AdultUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Terminated
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedRespiratory Distress Syndrome, AdultUnited States
Clinical Trials on Roflumilast
-
University of MiamiForest LaboratoriesCompleted
-
Rao DermatologyRecruitingHealthy SkinUnited States
-
Asan Medical CenterUnknownChronic Obstructive Pulmonary DiseaseKorea, Republic of
-
Arcutis Biotherapeutics, Inc.CompletedAtopic Dermatitis EczemaUnited States, Canada
-
FLUIDDA nvTerminatedPulmonary Disease, Chronic ObstructiveBelgium
-
AstraZenecaCompletedCOPDSweden, Germany, United States, Norway
-
AstraZenecaCompletedAsthmaUnited States, Russian Federation, Ukraine
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseChina
-
AstraZenecaCompleted
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease | COPDUnited States, France, Poland, South Africa, Canada, Germany